Cox Bryan F.
Known title: Chief of ResearchCIK: 0001981787
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TriSalus Stock Rises After FDA Clears TriNav Advance. TriSalus Life Sciences shares climbed 15.6% following FDA clearance for its TriNav Advance product. This regulatory approval marks a significant milestone for the company's pipeline. The stock is currently testing key support levels after the recent price movement.
Transaction History
| TLSIW | ▼ Sell | Open Market | 296 | $1K | 10/5/2026 | View on chart |
| TLSI | ▼ Sell | Open Market | 579 | $2K | 3/16/2026 | View on chart |
| TLSI | ▼ Sell | Open Market | 1,467 | $6K | 3/12/2026 | View on chart |
| TLSI | ▼ Sell | Open Market | 1,138 | $5K | 3/11/2026 | View on chart |
| TLSI | ▲ Buy | Grant | 40,000 | $0 | 11/24/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 15,722 | $81K | 5/19/2025 | View on chart |
| TLSI | ▼ Sell | Open Market | 4,764 | $25K | 5/19/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 11,450 | $0 | 2/18/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 10,625 | $0 | 1/27/2025 | View on chart |
| TLSI | ▼ Sell | Open Market | 314 | $1K | 10/5/2024 | View on chart |
| TLSI | ▲ Buy | Grant | 14,752 | $0 | 2/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
TriSalus Warrant Gains After FDA Clears TriNav Advance
TriSalus Life Sciences received FDA clearance for its TriNav Advance device, a move that strengthens its portfolio for liver embolization. This regulatory approval contributed to a 15.6% rise in the company's shares. The positive news provides context for the warrant's recent price action, which remains within its 52-week trading range.
TriSalus Warrant Gains After FDA Clears TriNav Advance. TriSalus Life Sciences received FDA clearance for its TriNav Advance device, a move that strengthens its portfolio for liver embolization. This regulatory approval contributed to a 15.6% rise in the company's shares. The positive news provides context for the warrant's recent price action, which remains within its 52-week trading range.